Skip to main content
Erschienen in: Clinical and Experimental Nephrology 2/2009

01.04.2009 | Review Article

The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions

verfasst von: Donald S. Silverberg, Dov Wexler, Adrian Iaina, Doron Schwartz

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

It has recently been recognized that many patients with congestive heart failure (CHF) are anemic. The anemia is very often associated with chronic kidney disease (CKD). The more severe the anemia the more severe the CHF, with higher mortality, morbidity, and hospitalization rate. The only way to prove that the anemia is itself a causative factor in the progression of both the CKD and the CHF is to correct it. In this paper we review the results of published papers and some preliminary reports about correction of this anemia in CHF. These studies frequently showed that erythropoietic stimulating agents (ESA) with oral or IV iron often resulted in improvement in left ventricular systolic and diastolic function, dilation, and hypertrophy, stabilization or improvement in renal function, reduced hospitalizations, diuretic dose, mitral regurgitation, pulmonary artery pressure, plasma volume, heart rate, serum brain natriuretic peptide levels, and the inflammatory markers C reactive protein and Interleukin 6, and an improvement in New York Heart Association class, exercise capacity, oxygen utilization during exercise, sleep apnea, caloric intake, depression, and quality of life. The activity of endothelial progenitor cells was also increased. Iron deficiency may also play an important role in the anemia, because significant improvement of cardiac, renal, and functional status in these anemic CKD–CHF has been seen after treatment with IV iron alone. Clearly more work is needed to clarify the relationship between anemia, CKD and CHF.
Literatur
1.
Zurück zum Zitat Hunt SA, Abraham WT, Chin MC, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. J Am Coll Cardiol. 2005;46:1116–43.CrossRef Hunt SA, Abraham WT, Chin MC, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. J Am Coll Cardiol. 2005;46:1116–43.CrossRef
2.
Zurück zum Zitat Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart disease and anemia. Semin Nephrol. 2006;26:296–306.CrossRefPubMed Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart disease and anemia. Semin Nephrol. 2006;26:296–306.CrossRefPubMed
3.
Zurück zum Zitat Lindenfeld JA. Prevalence of anemia and the effects on mortality in patients with heart failure. Am Heart J. 2005;149:340–91.CrossRef Lindenfeld JA. Prevalence of anemia and the effects on mortality in patients with heart failure. Am Heart J. 2005;149:340–91.CrossRef
4.
Zurück zum Zitat Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008 Feb (ahead of print). Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008 Feb (ahead of print).
5.
Zurück zum Zitat Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val–Heft. Circulation. 2005;112:1121–7.CrossRefPubMed Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val–Heft. Circulation. 2005;112:1121–7.CrossRefPubMed
6.
Zurück zum Zitat Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1441–6.CrossRef Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27:1441–6.CrossRef
7.
Zurück zum Zitat Tang WHW, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-term prognosis of new-onset, transient and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569–76.CrossRefPubMed Tang WHW, Tong W, Jain A, Francis GS, Harris CM, Young JB. Evaluation and long-term prognosis of new-onset, transient and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569–76.CrossRefPubMed
8.
Zurück zum Zitat Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–44.CrossRefPubMed Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function, functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–44.CrossRefPubMed
9.
Zurück zum Zitat Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anemia in diabetics and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141–6.CrossRefPubMed Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anemia in diabetics and non diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141–6.CrossRefPubMed
10.
Zurück zum Zitat Vaisman N, Silverberg DS, Wexler D, et al. Correction of anemia in patients with congestive heart failure increases resting energy expenditure. Clin Nutr. 2004;23:355–61.CrossRefPubMed Vaisman N, Silverberg DS, Wexler D, et al. Correction of anemia in patients with congestive heart failure increases resting energy expenditure. Clin Nutr. 2004;23:355–61.CrossRefPubMed
11.
Zurück zum Zitat Silverberg DS, Wexler D, Blum M, et al. Effects of treatment with EPO beta on outcomes in patients with anaemia and chronic renal failure. Kidney Blood Press Res. 2005;28:41–7.CrossRefPubMed Silverberg DS, Wexler D, Blum M, et al. Effects of treatment with EPO beta on outcomes in patients with anaemia and chronic renal failure. Kidney Blood Press Res. 2005;28:41–7.CrossRefPubMed
12.
Zurück zum Zitat George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res. 2005;68:299–306.CrossRefPubMed George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res. 2005;68:299–306.CrossRefPubMed
13.
Zurück zum Zitat Zilberman M, Silverberg DS, Bits I, et al. Improvement of anemia with erythropoietin and intravenous iron reduces sleep related breathing disorders (SRBD) and improves daytime sleepiness in anemic congestive heart failure (CHF) patients. Am Heart J. 2007;154:870–6.CrossRefPubMed Zilberman M, Silverberg DS, Bits I, et al. Improvement of anemia with erythropoietin and intravenous iron reduces sleep related breathing disorders (SRBD) and improves daytime sleepiness in anemic congestive heart failure (CHF) patients. Am Heart J. 2007;154:870–6.CrossRefPubMed
14.
Zurück zum Zitat Silverberg DS, Sheps D, Wexler D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–80.CrossRefPubMed Silverberg DS, Sheps D, Wexler D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–80.CrossRefPubMed
15.
Zurück zum Zitat Comin-Colet J, Ruiz-Ruiz V, Ortega A et al. Influence of neurohormonal activation and outcome of correction of mild anemia with intravenous iron and erythropoietin in patients with chronic heart failure and cardio-renal-anemia syndrome. Eur Heart J. 2006;28:Abstract 269. Comin-Colet J, Ruiz-Ruiz V, Ortega A et al. Influence of neurohormonal activation and outcome of correction of mild anemia with intravenous iron and erythropoietin in patients with chronic heart failure and cardio-renal-anemia syndrome. Eur Heart J. 2006;28:Abstract 269.
16.
Zurück zum Zitat Cosyns B, Lancellotti P, Velez-Roa S, Mantia M, Pierard LA. Does treatment with erythropoietin improve left ventricular systolic performance and mitral regurgitation in anemic patients with chronic heart failure and renal insufficiency? Eur Heart J. 2006;27: Abstract 339. Cosyns B, Lancellotti P, Velez-Roa S, Mantia M, Pierard LA. Does treatment with erythropoietin improve left ventricular systolic performance and mitral regurgitation in anemic patients with chronic heart failure and renal insufficiency? Eur Heart J. 2006;27: Abstract 339.
17.
Zurück zum Zitat Pappas KD, Gouva CD, Katopodis KP, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther. 2007;22:37–44.CrossRefPubMed Pappas KD, Gouva CD, Katopodis KP, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. Cardiovasc Drugs Ther. 2007;22:37–44.CrossRefPubMed
18.
Zurück zum Zitat Mancini DM, Katz SD, Lang C, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–9.CrossRefPubMed Mancini DM, Katz SD, Lang C, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–9.CrossRefPubMed
19.
Zurück zum Zitat Parissis JT, Kourea K, Panou F et al. Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.e1–7.CrossRefPubMed Parissis JT, Kourea K, Panou F et al. Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.e1–7.CrossRefPubMed
20.
Zurück zum Zitat Kourea K, Parissis JT, Farmakis D et al. Effects of darbepoetin-alfa on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin 10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis. 2008;199:215–21.CrossRefPubMed Kourea K, Parissis JT, Farmakis D et al. Effects of darbepoetin-alfa on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin 10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis. 2008;199:215–21.CrossRefPubMed
21.
Zurück zum Zitat Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alfa on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2008;15:365–9.CrossRefPubMed Kourea K, Parissis JT, Farmakis D, et al. Effects of darbepoetin-alfa on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2008;15:365–9.CrossRefPubMed
22.
Zurück zum Zitat Palazzuoli A, Silverberg DS, Iovine F, et al. Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152: 1096e9–15.CrossRef Palazzuoli A, Silverberg DS, Iovine F, et al. Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152: 1096e9–15.CrossRef
23.
Zurück zum Zitat Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta Erythropoietin on left ventricular remodeling, systolic function and beta-type Natriuretic peptide levels in patients with cardio-renal anemia syndrome. Am Heart J. 2007;154:645e9–15.CrossRef Palazzuoli A, Silverberg DS, Iovine F et al. Effects of beta Erythropoietin on left ventricular remodeling, systolic function and beta-type Natriuretic peptide levels in patients with cardio-renal anemia syndrome. Am Heart J. 2007;154:645e9–15.CrossRef
24.
Zurück zum Zitat Ghali JK, Anand IS, Abraham WT et al. The effects of increased hemoglobin concentration on clinical outcomes in patients with symptomatic heart failure and anemia: results from STAMINA–Heft. Am Heart Assoc meeting Chicago. Nov 2006: Abstract 2736. Ghali JK, Anand IS, Abraham WT et al. The effects of increased hemoglobin concentration on clinical outcomes in patients with symptomatic heart failure and anemia: results from STAMINA–Heft. Am Heart Assoc meeting Chicago. Nov 2006: Abstract 2736.
25.
Zurück zum Zitat Ghali J, Anand I, Abraham WT, et al. Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–35.CrossRefPubMed Ghali J, Anand I, Abraham WT, et al. Randomized double blind trial of darbepoetin alpha treatment in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–35.CrossRefPubMed
26.
Zurück zum Zitat Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized double blind placebo-controlled trial to evaluate the effect of two dosing regimens of darbepoetin alpha in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208–16.CrossRefPubMed Van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized double blind placebo-controlled trial to evaluate the effect of two dosing regimens of darbepoetin alpha in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208–16.CrossRefPubMed
27.
Zurück zum Zitat Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol. 2007;49:753–62.CrossRefPubMed Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure. J Am Coll Cardiol. 2007;49:753–62.CrossRefPubMed
28.
Zurück zum Zitat Abraham WT, Klapholz M, Anand I et al. The effect of darbepoetin alfa treatment on clinical outcomes on anemic patients with symptomatic heart failure: a preplanned pooled analysis of two randomized, double-blind, placebo-controlled trials. Eur J Heart Fail. 2006; 5 Suppl: Abstract 548. Abraham WT, Klapholz M, Anand I et al. The effect of darbepoetin alfa treatment on clinical outcomes on anemic patients with symptomatic heart failure: a preplanned pooled analysis of two randomized, double-blind, placebo-controlled trials. Eur J Heart Fail. 2006; 5 Suppl: Abstract 548.
29.
Zurück zum Zitat Bennett CL, Silver SM, Djulbegovic BT, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.CrossRefPubMed Bennett CL, Silver SM, Djulbegovic BT, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.CrossRefPubMed
30.
Zurück zum Zitat Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American society of hematology/American society of clinical oncology clinical practice guideline update. Blood. 2008;111:25–41.CrossRefPubMed Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American society of hematology/American society of clinical oncology clinical practice guideline update. Blood. 2008;111:25–41.CrossRefPubMed
31.
Zurück zum Zitat Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;39:584–90.CrossRef Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;39:584–90.CrossRef
32.
Zurück zum Zitat Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.CrossRefPubMed Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.CrossRefPubMed
33.
Zurück zum Zitat Drueke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.CrossRefPubMed Drueke TB, Locatelli F, Clyne N, et al. Normalization of haemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.CrossRefPubMed
34.
Zurück zum Zitat Strippoli GFM, Tognoni G, Navaneethan SK, Nicolluci A, Craig JC. Haemoglobin targets: we were wrong, time to move on. Lancet. 2007;369:346–50.CrossRefPubMed Strippoli GFM, Tognoni G, Navaneethan SK, Nicolluci A, Craig JC. Haemoglobin targets: we were wrong, time to move on. Lancet. 2007;369:346–50.CrossRefPubMed
35.
Zurück zum Zitat Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–8.CrossRefPubMed Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target hemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369:381–8.CrossRefPubMed
36.
Zurück zum Zitat Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14–31.CrossRefPubMed Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14–31.CrossRefPubMed
37.
Zurück zum Zitat Bolger AP, Bartlett FP, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225–7.CrossRefPubMed Bolger AP, Bartlett FP, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225–7.CrossRefPubMed
38.
Zurück zum Zitat Toblli J, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT- pro-BNP in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–65.CrossRefPubMed Toblli J, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT- pro-BNP in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–65.CrossRefPubMed
39.
Zurück zum Zitat Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency. J Nephrol. 2008;21:236–42.PubMed Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency. J Nephrol. 2008;21:236–42.PubMed
40.
Zurück zum Zitat Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol. 2008;51:103–12.CrossRefPubMed Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. J Am Coll Cardiol. 2008;51:103–12.CrossRefPubMed
41.
Zurück zum Zitat Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26:2232–7.CrossRefPubMed Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26:2232–7.CrossRefPubMed
42.
Zurück zum Zitat Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485–9.CrossRefPubMed Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485–9.CrossRefPubMed
43.
Zurück zum Zitat Anand IS. Heart Failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008 (ahead of print). Anand IS. Heart Failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008 (ahead of print).
44.
Zurück zum Zitat Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV Iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007;8:975–84.CrossRef Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients’ response to IV Iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007;8:975–84.CrossRef
45.
Zurück zum Zitat Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372–9.CrossRefPubMedPubMedCentral Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372–9.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Gotloib L, Silverberg DS, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161–7.PubMed Gotloib L, Silverberg DS, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161–7.PubMed
47.
Zurück zum Zitat Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006;21:120–4.CrossRefPubMed Mircescu G, Garneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients. Nephrol Dial Transplant. 2006;21:120–4.CrossRefPubMed
48.
Zurück zum Zitat Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anemias. Eur J Clin Invest. 2005;35 Suppl 3:36–45.CrossRefPubMed Weiss G, Gordeuk VR. Benefits and risks of iron therapy for chronic anemias. Eur J Clin Invest. 2005;35 Suppl 3:36–45.CrossRefPubMed
49.
Zurück zum Zitat Sengolge G, Horl WH, Sunder-Plassmann GS. Intravenous iron therapy: well tolerated but not harmless. Eur J Clin Invest. 2005;35 Suppl 3:46–51.CrossRefPubMed Sengolge G, Horl WH, Sunder-Plassmann GS. Intravenous iron therapy: well tolerated but not harmless. Eur J Clin Invest. 2005;35 Suppl 3:46–51.CrossRefPubMed
50.
Zurück zum Zitat Kang JO, Jones C, Brothwell B. Toxicity associated with iron overload found in hemochromatosis: possible mechanism in a rat model. Clin Lab Sci. 1998;11:350–4.PubMed Kang JO, Jones C, Brothwell B. Toxicity associated with iron overload found in hemochromatosis: possible mechanism in a rat model. Clin Lab Sci. 1998;11:350–4.PubMed
51.
Zurück zum Zitat Maruyama Y, Nakayama M, Yoshimura K, et al. Effect of repeated intravenous iron administration in hemodialysis patients on serum 8-hydroxy-2′-deoxyguanosine levels. Nephrol Dial Transplant. 2007;22:1407–12.CrossRefPubMed Maruyama Y, Nakayama M, Yoshimura K, et al. Effect of repeated intravenous iron administration in hemodialysis patients on serum 8-hydroxy-2′-deoxyguanosine levels. Nephrol Dial Transplant. 2007;22:1407–12.CrossRefPubMed
52.
Zurück zum Zitat Yoshimura K, Nakano H, Yokoyama K, Nakayama M. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis. Clin Exp Nephrol. 2005;9:158–63.CrossRefPubMed Yoshimura K, Nakano H, Yokoyama K, Nakayama M. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis. Clin Exp Nephrol. 2005;9:158–63.CrossRefPubMed
53.
Zurück zum Zitat Nakamura T, Keep RF, Hua Y, Nagao S, Hoff JT, Xi G. Iron-induced oxidative brain injury after experimental intracerebral hemorrhage. Acta Neurochir Suppl. 2006;96:194–8.CrossRefPubMed Nakamura T, Keep RF, Hua Y, Nagao S, Hoff JT, Xi G. Iron-induced oxidative brain injury after experimental intracerebral hemorrhage. Acta Neurochir Suppl. 2006;96:194–8.CrossRefPubMed
54.
Zurück zum Zitat Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623–32.CrossRefPubMed Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15:1623–32.CrossRefPubMed
55.
Zurück zum Zitat Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–80.CrossRefPubMed Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3070–80.CrossRefPubMed
56.
Zurück zum Zitat Hoen B, Paul-Dauphin M, Hestin D, Krssler M. EPIBACTIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869–76.PubMed Hoen B, Paul-Dauphin M, Hestin D, Krssler M. EPIBACTIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998;9:869–76.PubMed
57.
Zurück zum Zitat Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol. 2000;53 Suppl 1: S18–22.PubMed Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol. 2000;53 Suppl 1: S18–22.PubMed
58.
Zurück zum Zitat Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol. 2000;53 Suppl 1: S30–5.PubMed Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol. 2000;53 Suppl 1: S30–5.PubMed
59.
Zurück zum Zitat Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med. 2007;356:959–61.CrossRefPubMed Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med. 2007;356:959–61.CrossRefPubMed
60.
Zurück zum Zitat van Veldhuisen DJ, McMurray JJV. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomized outcome trial. Eur Heart J. 2007;9:110–2.CrossRef van Veldhuisen DJ, McMurray JJV. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomized outcome trial. Eur Heart J. 2007;9:110–2.CrossRef
61.
Zurück zum Zitat Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients—a critical review. Semin Dial. 2008;21:1–6.CrossRefPubMed Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients—a critical review. Semin Dial. 2008;21:1–6.CrossRefPubMed
63.
Zurück zum Zitat Young JB, Abraham WY, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE–HF registry). Am J Cardiol. 2008;101:223–30.CrossRefPubMed Young JB, Abraham WY, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE–HF registry). Am J Cardiol. 2008;101:223–30.CrossRefPubMed
64.
Zurück zum Zitat Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Cardiac Fail. 2006;12:257–62.CrossRef Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients. J Cardiac Fail. 2006;12:257–62.CrossRef
65.
Zurück zum Zitat De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201–13.CrossRefPubMed De Luca L, Mebazaa A, Filippatos G, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur J Heart Fail. 2008;10:201–13.CrossRefPubMed
Metadaten
Titel
The correction of anemia in patients with the combination of chronic kidney disease and congestive heart failure may prevent progression of both conditions
verfasst von
Donald S. Silverberg
Dov Wexler
Adrian Iaina
Doron Schwartz
Publikationsdatum
01.04.2009
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 2/2009
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-008-0074-1

Weitere Artikel der Ausgabe 2/2009

Clinical and Experimental Nephrology 2/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.